Top Markets
Coin of the day
Peak Bio, Inc. Peak Bio, Inc.

Peak Bio, Inc.

PKBO
Clasificación en acciones #37553
Peak Bio, Inc. is a biopharmaceutical firm currently in the clinical... Peak Bio, Inc. is a biopharmaceutical firm currently in the clinical development phase, committed to devising treatments for critical, unmet medical needs in the realms of oncology and inflammatory disorders. The company harnesses its unique, proprietary toxin—known as PH-1 or Thailanstatin—a spliceosome modulator, to create its inaugural range of innovative Antibody-Drug Conjugate (ADC) therapies designed for cancer patients facing significant challenges. Additionally, Peak Bio's leading investigational drug, PHP-303, a small molecule, is on the verge of commencing a Phase II dose clinical trial for the rare condition Alpha1 anti-trypsin deficiency (AATD). The company's operations are situated in Palo Alto, California.
Precio por acción
$0.07
Última sincronización: 2024-11-12
Capitalización bursátil
$1.62M
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio Peak Bio, Inc. (PKBO)

Categoría

Ratio P/S de Peak Bio, Inc. (PKBO)
Ratio P/S al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Peak Bio, Inc., el ratio P/S actual (TTM) es 0. Al final de 2026, el ratio P/S era 0.
Historial del ratio P/S de Peak Bio, Inc. desde 2026 hasta 2026
Ratio P/S al final de cada año
Año Ratio P/S Cambiar
Not enough data for the provided dates.
Ratio P/S de empresas similares o competidoras
Empresa Ratio P/S Diferencia del ratio P/S País
10.17 -
US
10.13 -
NL
- -
CH
- -
KR
4.74 -
BE